Hyperbaric Oxygen Treatment for Opioid Use Disorder
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests whether hyperbaric oxygen therapy (HBOT)—breathing pure oxygen in a pressurized room—can help reduce methadone doses by easing opioid withdrawal symptoms. It compares two different oxygen pressures to a placebo treatment. Individuals on methadone in a supervised opioid treatment program who wish to lower their dose may be suitable candidates, especially if withdrawal symptoms disrupt daily life. As a Phase 1 trial, the research focuses on understanding how the treatment works in people, offering participants a chance to be among the first to receive this innovative therapy.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications, but you cannot participate if you are taking Antabuse for alcohol addiction.
What prior data suggests that hyperbaric oxygen treatment is safe for opioid use disorder?
Research has shown that hyperbaric oxygen treatment (HBOT) could be a safe option for individuals undergoing opioid withdrawal. In earlier studies, participants who received HBOT at various pressure levels reported less pain and fewer drug cravings. These studies did not identify any major safety concerns, indicating that the treatment is generally well-tolerated.
During HBOT, participants breathe 100% oxygen in a pressurized chamber. This method is used in other treatments and is typically considered safe. Some minor side effects, such as ear discomfort, might occur due to pressure changes, but no serious issues were reported in the studies.
Overall, this treatment appears well-tolerated and offers a non-drug option to help reduce opioid use.12345Why are researchers excited about this trial's treatments?
Researchers are excited about hyperbaric oxygen treatment (HBOT) for opioid use disorder because it offers a novel approach compared to traditional therapies like medication-assisted treatments (MAT) with methadone, buprenorphine, or naltrexone. Unlike these standard medications that work by interacting with opioid receptors to reduce cravings and withdrawal symptoms, HBOT involves administering 100% oxygen at increased atmospheric pressures, which may promote brain healing and reduce dependency. This method is particularly intriguing because it targets the brain's recovery in a physical way, potentially offering benefits beyond just managing symptoms. With the potential to aid in neural repair and enhance recovery, HBOT represents a fresh avenue for treating opioid use disorder.
What evidence suggests that hyperbaric oxygen treatment might be an effective treatment for opioid use disorder?
Research shows that hyperbaric oxygen therapy (HBOT) might help ease symptoms of opioid withdrawal. In this trial, participants will join different treatment arms. Some will receive full HBOT, involving 100% oxygen at 2.0 ATA, while others will receive a partial pressure treatment with 100% oxygen at 1.3 ATA. A sham treatment arm will provide participants with 21% oxygen at 1.3 ATA. Studies have found that patients who received full HBOT reported better pain management and fewer drug cravings than those who received a sham treatment. HBOT has been particularly effective in reducing withdrawal symptoms and helping patients decrease their methadone doses. Early findings suggest that HBOT sessions lasting 90 minutes on two consecutive days can significantly improve the withdrawal experience. Overall, these initial results are promising for using HBOT as a supportive treatment for opioid use disorder.12345
Who Is on the Research Team?
Layton Matt, MD
Principal Investigator
Washington State University
Are You a Good Fit for This Trial?
This trial is for adults over 18 who are enrolled in a supervised opioid treatment program at the Spokane Regional Health District. Participants must be able to read, speak, and write English and provide written informed consent.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive hyperbaric oxygen therapy (HBOT) at different pressures or sham treatment during methadone tapering
Follow-up
Participants are monitored for safety and effectiveness after treatment
Long-term follow-up
Participants' methadone dose changes are assessed at one month and three months from baseline
What Are the Treatments Tested in This Trial?
Interventions
- Hyperbaric Oxygen Treatment
Hyperbaric Oxygen Treatment is already approved in United States, European Union, Canada for the following indications:
- Carbon monoxide poisoning
- Decompression sickness
- Diabetic foot ulcers
- Wound healing
- Carbon monoxide poisoning
- Decompression sickness
- Diabetic foot ulcers
- Wound healing
- Radiation necrosis
- Carbon monoxide poisoning
- Decompression sickness
- Diabetic foot ulcers
- Wound healing
Find a Clinic Near You
Who Is Running the Clinical Trial?
Washington State University
Lead Sponsor